Cargando…
The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In this perspective,...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651948/ https://www.ncbi.nlm.nih.gov/pubmed/31340855 http://dx.doi.org/10.1186/s13073-019-0661-7 |